Jess Oren, MD
Cardiovascular Disease · Danville, PANPI 1114980901
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,951 of the $3,891 with a category attached, or 75.9%. Abbott accounts for 81.4% of it on its own, with 2 other manufacturers making up the rest.
Across 25 payments — averaging $155.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$467
- Philips North America LLC$254
Across 142 payments — averaging $4264.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$573K
- Boston Scientific$32K
What the payments were for
- Travel & lodging$2,95176%
- Food & beverage$93224%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $3,169 |
| Medtronic | 3 | $467 |
| Philips North America LLC | 1 | $254 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,727
- Azurion 7 M20$254
How this compares
$3,891 in reported general payments places this provider in the 70th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 285 | $337,868 |
| XareltoRivaroxaban | 78 | $82,712 |
| Dofetilide | 99 | $13,275 |
| Flecainide Acetate | 121 | $9,538 |
| Metoprolol Succinate | 217 | $4,721 |
| Amiodarone Hcl | 182 | $4,477 |
| SotalolSotalol Hcl | 83 | $2,217 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 63 | $1,661 |
| Dilt-XrDiltiazem Hcl | 12 | $849 |
| Warfarin Sodium | 50 | $846 |
| Potassium Chloride | 22 | $718 |
| Atorvastatin Calcium | 41 | $615 |
| Torsemide | 15 | $574 |
| Losartan Potassium | 33 | $534 |
| Furosemide | 81 | $512 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Danville
- Dominik BeerDanville$87K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.